Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 4/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577558 | 0.97 | MT-CO2 (0.47) | MT-CO2PRKAA2GPR6CXCR3TP53 | |
| SCHEMBL5577827 | 0.89 | ALDH1A1 (0.42) | MAPTKDM4E | |
| SCHEMBL5577599 | 0.85 | P2RX7 (0.46) | MT-CO2MAPTKDM4EGPR6PIK3CD | |
| SCHEMBL5577778 | 0.85 | ALDH1A1 (0.44) | MAPTKDM4E | |
| SCHEMBL5577671 | 0.84 | MT-CO2 (0.43) | MT-CO2PRKAA2CXCR3 | |
| SCHEMBL5577697 | 0.84 | MT-CO2 (0.43) | MT-CO2CXCR3TP53 | |
| SCHEMBL5577531 | 0.84 | MT-CO2 (0.54) | MT-CO2MAPTKDM4EPRKAA2TP53 | |
| SCHEMBL5577678 | 0.83 | MT-CO2 (0.44) | MT-CO2OPRM1OPRK1MAPTKDM4E | |
| SCHEMBL5577738 | 0.83 | OPRM1 (0.52) | OPRM1OPRK1MAPTPRKAA2CXCR3 | |
| SCHEMBL5577406 | 0.82 | MT-CO2 (0.47) | MT-CO2OPRM1OPRK1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MT-CO2 2047/4885OPRM1 584/4885OPRK1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.